Insights
Analysis & Commentary
Deep dives into the biotech landscape — IP strategy, clinical development, market dynamics, and regulatory trends.
The ANDA Threat Landscape in 2026: What Brand Pharma Needs to Know
This post examines the current ANDA filing landscape using FDA data through January 2026 and outlines the strategic considerations that should inform any brand's response.
Read more →
Highlights From the Mass General Brigham 2025 Gene and Cell Therapy Institute Research Symposium
Coverage of trends and insights from the 2025 Mass General Brigham Gene and Cell Therapy Research Symposium, featuring keynotes from Dr. Carl June and Dr. David Liu.
Read more →
IP Review: Tessera's Therapy for Alpha-1 Antitrypsin Deficiency Disease - Engineering a $150M Gene Editor
A deep-dive into the engineering behind TSRA-196, Tessera and Regeneron's in vivo gene editing therapy for AATD, and the IP strategy protecting it.
Read more →